Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis. The company said the tablet form provides an additional treatment option alongside the existing liquid formulation. Livmarli tablets are planned to be available in June through Mirum Access Plus.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Strategic Advancements and Market Potential Drive Buy Rating for Mirum Pharmaceuticals
- Mirum Pharmaceuticals partner Takeda receives approval for Livmarli in Japan
- Mirum Pharmaceuticals: Promising Growth Trajectory with Strategic Focus and Pipeline Progress
- Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements
- Mirum Pharmaceuticals’ Earnings Call Highlights Growth and Future Prospects